2023 World Conference on Lung Cancer (Posters)-EP09.01. Hypofractionated Radiotherapy for Elderly Lung Cancer Patients

EP09.01. Hypofractionated Radiotherapy for Elderly Lung Cancer Patients - PDF(Slides)

Pdf Summary

A study evaluated the outcomes of hypofractionated radiotherapy (HFX) for elderly lung cancer patients. The study included 52 patients, with a median age of 80 years. HFX was used to target the primary, recurrent, or progressed tumor, with a median radiation dose of 45 Gy and a median of 13 fractions. The median follow-up duration was 13.2 months, and the overall survival was 13.2 months. Outcomes showed that 86.5% of patients responded to treatment at a median of 33 days after the end of radiation therapy. The 1-year rates of local relapse-free survival, regional relapse-free survival, and distant relapse-free survival were 89.6%, 80.0%, and 95.3% respectively. Symptomatic radiation pneumonitis, grade 2, occurred in 13.5% of patients, while no patients experienced grade 3 radiation pneumonitis. The study concluded that HFX for elderly lung cancer patients achieved acceptable disease control rates and radiation pneumonitis levels for 1 year. However, further follow-up and studies with more patients are needed to confirm these outcomes. Hypofractionated radiotherapy may be a suitable treatment option for elderly patients with lung cancer who may not be candidates for surgery, chemotherapy, or conventional fractionated radiotherapy. HFX offers improved time efficiency and convenience. Overall, HFX showed promising results in terms of disease control and side effects for elderly lung cancer patients.

Asset Subtitle

Jeong Won Lee

Meta Tag

Speaker Jeong Won Lee

Topic Metastatic NSCLC: Local Therapies - Effects

Keywords

hypofractionated radiotherapy

HFX

elderly lung cancer patients

radiation dose

fractionation

follow-up duration

overall survival

relapse-free survival

radiation pneumonitis

disease control